TBI & Spinal Cord Injury Research Reagents

Traumatic brain injury (TBI) and spinal cord injury (SCI) involve primary mechanical damage followed by secondary injury cascades including neuroinflammation, excitotoxicity, and reactive gliosis. FDA-cleared blood biomarkers (GFAP, UCH-L1) now enable rapid mild TBI triage, while NfL and S100B are emerging as prognostic markers. Research focuses on neuroprotection, axon regeneration, and rehabilitation biomarkers.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

TBI & Spinal Cord Injury Research Reagents - key pathogenic pathways and research targets

Fig. 1 Key pathogenic pathways and research targets. abinScience product targets highlighted in orange.

abinScience provides validated antibodies, recombinant proteins, and ELISA kits for key TBI and spinal cord injury research targets. All products are manufactured by our parent company AtaGenix Laboratories under ISO quality systems. Browse products below or contact us for custom antibody development.

Key Research Targets

GFAP — Serum GFAP is an FDA-cleared biomarker for mild TBI evaluation (Banyan Brain Trauma Indicator). Anti-GFAP antibodies support point-of-care assay development and astrocyte damage quantification in neurotrauma research.
→ Browse GFAP antibodies & ELISA kits

UCH-L1 — UCH-L1 (ubiquitin C-terminal hydrolase L1) is released from damaged neurons and is an FDA-cleared TBI biomarker paired with GFAP. Anti-UCH-L1 antibodies enable neuronal injury detection in serum and CSF.
→ Browse UCH-L1 antibodies & proteins

NfL (Neurofilament Light Chain) — Serum NfL reflects axonal damage severity in TBI and SCI, correlating with injury severity and long-term outcomes. Anti-NfL antibodies support prognostic assay development and rehabilitation monitoring.

References

1. Maas AIR, et al. Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. Lancet Neurol. 2017;16(12):987-1048. DOI

2. Bazarian JJ, et al. Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI). Lancet Neurol. 2018;17(9):782-789. DOI

3. Ahadi R, et al. Diagnostic value of serum levels of GFAP, pNF-H, and NSE compared with clinical findings in severity assessment of human traumatic spinal cord injury. Spine. 2015;40(14):E823-830. DOI